Glenmark confirms reaching agreement with Roche over patent disputes
January 5, 2016The Indian Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned “Roche, Glenmark Settle Patent suit over cancer drug”.
As a response, the company on Tuesday said it has vide email dated January 04, 2016 has submitted that Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine – Erlotinib Hydrochloride.
“As part of the agreement, the companies have ceased all relevant patent litigation on this product. The settlement is a part of normal course of our business and it will have no material impact on the company,” it has been revealed in the company’s press release.